Global Polycystic Ovarian Syndrome Treatment Market Expected to Reach $4,184 Million by 2026

According to a new report published by Allied Market Research, titled, "Polycystic Ovarian Syndrome Treatment Market by Drug Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global polycystic ovarian syndrome treatment market size was valued at $2,902 million in 2018, and is projected to reach $4,184  million by 2026, growing at a CAGR of 4.7% from 2019 to 2026. 

Polycystic ovarian syndrome or PCOS is a hormonal disorder that occurs in women during their childbearing age and is characterized by formation of cyst on ovaries. PCOS often leads to hirsutism, obesity, infertility, and diabetes, thus, needs effective management. Presently, there is no cure for PCOS, but different types of medications, such as insulin sensitizing agent, oral contraceptive, antiandrogens, and anti-obesity drugs are used to manage PCOS. 

The polycystic ovarian syndrome treatment market is expected to experience significant growth during the forecast period owing to rise in demand for PCOS treatment medication across different regions and increase in popularity combination therapy majorly drives the market growth. Increase in prevalence of PCOS is expected to further boost the polycystic ovarian syndrome treatment market growth during the forecast period. In addition, significant unmet need for PCOS treatment, increase in R&D activities to develop PCOS therapeutics, and growing demand forof PCOS therapeutics in developing countries further creates opportunities for the PCOS treatment market. However, lack of approved drugs and adverse effects associated with off label drugs are anticipated to hamper the market growth. 

On the basis of drug class, the market is categorized into insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. Presently, the insulin sensitizing agent segment is the major revenue contributing segment and is estimated to show a significant market growth during the forecast period, owing to higher adoption of insulin sensitizing agents as first line treatment in the management of PCOS. 

According to distribution channel, the polycystic ovarian syndrome treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, attributed to the rise in preference for online purchasing of drugs over traditional methods, increase in awareness of online pharmacy, and rise in number of internet users.

Key Findings of the Study:

• Based on drug class, the insulin sensitizing agent segment held more than one half of share in the global market in 2018.
• Based on end user, the online providers segment exhibits fastest growth and is expected to grow at a CAGR of 6.3% from 2019 to 2026. 
• Based on end user, the drug stores & retail pharmacies segment held the largest market share in 2018 and is expected to remain dominant throughout the forecast period. 
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.3% during the forecast period. 

North America accounted for approximately one-half of the global polycystic ovarian syndrome treatment market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to the rise in adoption of polycystic ovarian syndrome treatment medications, well developed healthcare infrastructure, large number of target population with higher health awareness, wide availability of advanced polycystic ovarian syndrome treatment therapeutics, and supportive reimbursement policies in the healthcare system. In addition, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growing prevalence of PCOS, and increase in the adoption of polycystic ovarian syndrome treatment medication for the same.